LASA SUPERGENERICS

LASA SUPERGENERICS Q1FY21 PAT AT 5.37 CRS,
UP 437% YOY

Lasa Supergenerics Limited, a vertically integrated group spanning the entire animal and human healthcare value chain has announced its financial results for the first quarter ended June 30^th 2020 (Q1FY21)

 Q1FY21 performance overview compared with Q4FY20                                                                                                                                                                    

·         Revenues from operations stood at Rs. 54.60 crore as against Rs. 48.58 crore in Q4FY20

·         EBITDA of Rs. 12.20 crore as compared to Rs. 9.01 crore in Q4FY20

o   EBITDA margins at 22.34%

• PAT stood at Rs. 5.37 crore as compared to Rs.2.61 crore in Q4FY20

·         EPS for Q1FY21 stood at Rs. 1.32

 Q1FY21 performance overview compared with Q1FY20                                                                          

                                                                                               

·         Revenues from operations stood at Rs. 54.60 crore as against Rs. 38.98  crore in Q1FY20

·         EBITDA of Rs. 12.20 crore as compared to Rs. 5.06 crore in Q1FY20

o   EBITDA margins at 22.34% as against 12.98% in Q1FY20

• PAT stood at Rs.5.37 crore as against a loss of Rs.1.27 crore

·         EPS for Q1FY21 stood at Rs. 1.32 as compared to Rs. 0.47 in Q1FY20

For first quarter ended June 30^th 2020

• Revenues from operations for the first quarter ended June 30^th, 2020 (Q1FY21) stood at Rs. 54.60 crore.
  
  
• The Company reported Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) of Rs. 12.20 crore in Q1FY21, as against Rs 9.01 crore in Q4FY20; up 35.4%.
  The Company’s EBITDA margin stood at 22.34%
  
• The Company reported PAT of Rs. 5.37 crore for Q1FY21.The Company’s PAT margin stood at 9.84%
  
• Earnings per share (EPS) for the quarter ended Q1FY21 stood at Rs 1.32
  
• The Finance cost reduced by 45% Q-o-Q from Rs. 2.29 crore in Q4FY20 to Rs. 1.29 crore in Q1FY21

Commenting on the performance, Dr. Omkar Herlekar, Chairman – Lasa Supergenerics Limited, said,

“We have reported a good performance in our business in Q1 FY21 despite significant disruptions and ambiguity in the business environment. We are confident that the Company under its strong leadership and planned strategies will navigate through these difficult times. We have substantially brought down the debt.”

COVID 19: ICT, Lasa realise success in

COVID 19: ICT, Lasa realise success in Favipiravir drug synthesis, to commence production

Veterinary API Major, Lasa Supergenerics and Institute of Chemical Technology had come together in the month of March 2020 in effort to bring the antiviral to the market as a promising therapy to fight the ongoing Covid-19 pandemic.

Commenting on the development, Dr Omkar Herlekar, Chairman– Lasa Supergenerics Limited, said
Efforts over the last few months has brought success and we are looking to manufacture close to
10,000 doses to begin with and in the meanwhile also apply for the drug licence with competent
authorities and continue to seek strategic private investments or Government aid. Our move into
human steroid API is in line with the organisations inherent strengths and objectives to diversify.
Commenting on the antivirals successful synthesis, Prof. Vikas N Telvekar, ICT, Mumbai, said we
are happy to share with you that the Favipiravir molecule has been successfully synthesized in the
ICT laboratory on a lab scale and further pilot plan scale up is required.”

Recently in its Q4 results, the company reported a healthy increase in its PAT to Rs 3.63 cr for FY20,
as compared to a loss of Rs 12.04 cr in the corresponding period last fiscal
The stock ended at xxx high and xx low on June 17.

Lasa Supergenerics acquires

Lasa Supergenerics acquires Harishree Aromatics

Veterinary API major, Lasa Supergenerics Limited recently announced its acquisition of Harishree Aromatics And Chemicals Private Limited which is in the manufacturing of Veterinary API & Other Pharmaceuticals Intermediates.

In addition to the takeover of the manufacturing unit along with all other assets and liabilities whereas transferor is a debt free company, the amalgamation and consolidation will result in an increase in market share, product and services diversification, combined pool of reserves, investments and other assets giving it a competitive edge over its listed and unlisted peers

While the deal size has not been disclosed, the corporate announcement uploaded on the stock exchanges stated that on the scheme becoming effective shareholders of Harishree will be entitled to 1000 fully paid up shares of Lasa for every 35 equity shares held

Commenting on the acquisition, Dr. Omkar Herlekar, Chairman– Lasa Supergenerics Limited, said “This acquisition has been a strategic decision to restructure our current potential and a forward integrate. The amalgamation of both the entities stands to extract synergistic benefits, economies of scale, better cash flow management, optimisation of borrowing costs resulting in better financial and operational efficiencies and better shareholder value”

The company recently announced the third quarter and nine months ended results where it turned net positive. It declared revenue of Rs. 39.29 cr, EBITA of Rs. 8.16 cr which was up by 8.7%, EPS of Rs.0.89 as compared to a negative 2.31 and a PAT of Rs 2.57 cr against a loss of Rs.5.28 cr compared to the previous quarter. The company is working towards bringing down the finance costs and the working capital cycle.

The share price has been hitting new 52 week high record post Q3FY20 results and acquisition of new entity. The stock has achieved upper circuit for last six consecutive days with a total turnover of approx 32,90,089 and a 100% quantity deliverable.  The investors are cheering the inorganic growth strategy of the company and hope the trajectory will continue and will help to increase the value of the shareholders.